Boston Scientific: Tobin Broadens Horizons, LaViolette To Leave
This article was originally published in The Gray Sheet
Executive Summary
Boston Scientific CEO Jim Tobin will begin managing day-to-day operations across the company now that the firm's cardiac rhythm management business is stabilized, the firm said June 3
You may also be interested in...
Boston Scientific Predicts 2009 Will Be The Year Guidant Buy Proves Wise
Boston Scientific CEO Jim Tobin says 2009 will be the year when his company's gamble on cardiac rhythm management begins to pay off the way it hoped when it entered the CRM business by buying Guidant in 2006
Boston Scientific Predicts 2009 Will Be The Year Guidant Buy Proves Wise
Boston Scientific CEO Jim Tobin says 2009 will be the year when his company's gamble on cardiac rhythm management begins to pay off the way it hoped when it entered the CRM business by buying Guidant in 2006
People In Brief
LaViolette ventures from Boston Sci: Former Boston Scientific Chief Operating Officer Paul LaViolette will join venture capital firm SV Life Sciences next month as a venture partner in the company's Boston office and medical technology segment. LaViolette relinquished the COO position July 1 as part of an executive restructuring at Boston Scientific (1"The Gray Sheet" June 9, 2008, p. 8). LaViolette will leave the device firm outright at the end of the year after six months as a company advisor and about 15 years as a top executive. SVLS's device portfolio includes laser ablation firm CardioFocus, ventricular assist device company MicroMed, and diabetes product firm Insulet. The venture firm points out that LaViolette integrated more than 20 acquisitions during his time at Boston Scientific